Shelf Life, Stability and Transport Validation for Iran Registration

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Shelf life, stability and transport validation are the module whose weight is most underestimated in Iranian registration. The judgement of GRZAN is that Iran’s climatic conditions — high summer temperatures in some regions — together with long-distance transport make transport validation a substantive review item rather than a formal one. 3 consistencies must hold: the shelf life on the label, the shelf life supported by the stability data, and the duration covered by the transport validation — the three must not contradict one another. The three numbers come from three different work streams, which is exactly why they drift apart unless someone holds them together.

  • Shelf life, stability and transport validation carry more review weight in Iran than most applicants assume.
  • Iran’s climate and long-distance transport make transport validation a substantive review item, not a formality.
  • Three consistencies must hold at once: labelled shelf life, stability-supported shelf life, and transport validation duration. Check them as a set, not one by one.
  • Any contradiction among the three invites review questions and weakens an otherwise complete dossier. The check costs a meeting; the contradiction costs a review cycle.

2. Legal basis

The legal and normative references supporting this module are the following.

  1. Stability and transport validation requirements: Iranian review focuses on whether product performance is maintained under local climatic and transport conditions — this is a practical estimate, and the specific validation conditions are set according to the product characteristics and the installation site.
  2. Persian-language label and instructions for use requirements: the shelf life must be clearly marked on the label — based on publicly available industry materials; no official Iranian document number has been released through public channels, so this is a practical estimate.
  3. Law on the Administration of Medical, Pharmaceutical and Food-Beverage Affairs, FAOLEX LEX-FAOC227692, 1955-06-20, Article 3 (unauthorised changes to labels are prohibited).

3. Expert insights

Insight 1: the shelf life is a “commitment”, not an “estimate”. The shelf life marked on the label is a promise to the market, and it must stand on stability data — not on judgment, analogy or optimism. Every month claimed on the label is a month the data must support. This also means the shelf life cannot simply be revised when it turns out to be convenient: extending the shelf life is a change, and a change requires data to be submitted again through the change process. Changing the label directly on the market is prohibited. Companies that treat the shelf life as a marketing figure discover that the regulatory system treats it as an engineering figure, and the reconciliation is far more expensive than getting it right the first time. The change process exists precisely so that the label and the data move together. The label is read against the data, and the data are read against the label; neither can outrun the other.

Insight 2: cold-chain products need a complete temperature record chain. For reagents or products requiring refrigeration, the exposure that matters is the entire journey — from ex-factory to the Iranian end user — not the segments the applicant happens to control. A full-journey temperature recording plan must therefore be submitted, covering the recording equipment, the sampling frequency and the procedure for handling temperature excursions. The excursion procedure deserves particular care: what happens when a recording shows the limit was exceeded is exactly the question a reviewer asks, and an answer prepared in advance reads as competence while an answer improvised under questioning reads as improvisation. A cold chain without a record is, for review purposes, indistinguishable from no cold chain. The plan should also name who reads the recordings and who decides when an excursion has occurred. A recording that nobody reviews is a device, not a plan.

Insight 3: the remaining shelf life at the port is an invisible threshold in practice. Iranian practice sets requirements for the remaining shelf life of goods on arrival; a remaining shelf life that is too short affects customs clearance and market acceptance. This point is not found in any uniformly published official text — it is a practical estimate, and it must be confirmed in the contract and the logistics plan rather than assumed from general regulation. Because the requirement lives in commercial practice rather than in a published rule, the only reliable protection is contractual: agreeing a floor for the remaining shelf life on arrival with the importing party, so that neither side discovers the threshold at the port. Because the practice is unpublished, it can also change without notice, which is a further reason to keep it contractual rather than assumed.

4. Practical recommendations

  • Run the 3-item consistency check: cross-check the labelled shelf life, the stability data and the transport validation duration, and record the check in the dossier.
  • Submit the full recording method with the cold-chain plan: temperature recording equipment, sampling frequency, and the excursion handling procedure. The recording must cover the whole route, not only the segments under the applicant’s control.
  • Design the high-temperature transport validation around the actual route: set the validation parameters for Iranian summer conditions, using the highest temperatures the route is expected to see.
  • Lock the remaining shelf life in the contract: agree a floor for the remaining shelf life on arrival with the importing party; the threshold is agreed before shipment, not discovered at the port.

5. Verification checklist

  • □ Labelled shelf life, stability data and transport validation duration have been checked for consistency
  • □ Cold-chain products have a full-journey temperature recording plan and excursion handling procedure on file
  • □ High-temperature transport validation has been completed under Iranian summer conditions
  • □ The contract sets a floor for the remaining shelf life on arrival
  • □ Shelf life extension has been brought under change management; labels are not changed unilaterally

Regulatory information verified as of October 29, 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team prepares IFDA-compliant dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail